33 results about "Liver resections" patented technology

The invention discloses a preoperative risk stratification system based on hepatic resection after transformation treatment in the technical field of biomedicine, and the system comprises a sample module which is used for selecting a proper hepatocellular carcinoma patient as a sample, distributing the patient sample to a training queue and an internal verification queue, and building an external verification queue; the treatment module is used for providing a treatment strategy for the patient based on whether liver resection is performed or not after conversion treatment; the tracking module is used for carrying out regular follow-up visit on the patient subjected to the liver resection or not subjected to the liver resection after the conversion treatment; and the data analysis module is used for determining prediction factors related to recurrence-free survival in the training queue by adopting a minimum absolute contraction and selection operator regression analysis method, further analyzing and screening out independent prognosis factors through multivariable Cox regression, and constructing a column graph based on the factors to predict the postoperative recurrence rate. Through verification of the internal and external verification queues, the method can effectively guide and select a patient who is most likely to benefit from the liver resection operation after transformation treatment.

The invention relates to a computer-implemented method of liver resection surgery planning, comprising the steps of: processing (E2) preoperative computed tomographic images (10) of a patient to generate liver, liver lesion (ss) and venous vessels segmentations; pruning the venous vessels segmentation to retain only major vessels and determining (E3) a primary hepatic zone (PHZ) from the retained major vessels; determining (E4) at least one quantitative feature from the primary hepatic zone, the liver segmentation and the liver lesion(s) segmentation; processing (E5) the determined quantitative features with a classification model to determine a liver resection complexity score for the patient.

The invention discloses a bending-adjustable endoscope type liver cutting radiofrequency ablation electrode, and relates to the technical field of medical apparatuses and instruments. The device comprises a handle, the top of the handle is provided with a depth adjusting block, one side of the handle is provided with a trigger, the top of the trigger is provided with an extension rod, one side of the extension rod is fixedly connected with an adjustable bent pipe, and one side of the adjustable bent pipe is provided with a cutting electrode. Through the design of the adjustable bent pipe and the snake bone cutting structure, the front end of the instrument can realize multi-angle flexible bending, the surgical operation range is obviously expanded, the instrument is particularly suitable for areas such as the back of the liver which are difficult to directly touch, dependence on other auxiliary instruments is reduced, the flexibility and operability of the surgery are improved, and the surgical efficiency is improved. The depth limiting head is linked with the trigger, and the seven-gear design of the depth adjusting block is matched, so that the depth of the cutting electrode penetrating into the liver can be accurately controlled, excessive puncture or insufficient ablation is avoided, and the safety and effectiveness of an operation are improved.

The application provides a laparoscopic liver resection surgery registration method and system based on an artificial intelligence algorithm, and belongs to the technical field of image processing.The method carries out normalization processing on a preprocessed laparoscopic surgery image to obtain a normalized laparoscopic surgery image; an artificial intelligence algorithm is used to carry out contour extraction on the normalized laparoscopic surgery image to obtain the upper edge and the lower edge of the liver in the laparoscopic surgery image; a preoperative 3D liver model is constructed, and the upper edge and the lower edge of the liver are labeled in the constructed preoperative 3D liver model; the upper edge and the lower edge of the liver in the laparoscopic surgery image and the upper edge and the lower edge of the liver labeled in the constructed preoperative 3D liver model are subjected to registration calculation to obtain a registration result.Compared with the prior art, the application effectively solves the problem that the accuracy of laparoscopic liver resection surgery registration is not high.

The invention discloses application of a CGAS-STING signal channel inhibitor in preparation of a medicine for preventing and treating hepatic ischemia-reperfusion injury, and relates to the technical field of biological medicine. According to the application, a cGAS-STING signal channel in macrophages is inhibited by using a cGAS inhibitor or an STING inhibitor, activation of double-stranded deoxyribonucleic acid released by a neutrophile granulocyte extracellular trapping net on a DNA induction channel is blocked, and the M1 type polarization level of the macrophages is reduced. The traditional Chinese medicine composition can effectively relieve liver inflammatory response and cell apoptosis, and a new path is provided for preventing and treating acute liver injury after liver transplantation or liver resection.

The invention discloses a method for constructing a liver injury animal model, which comprises the following steps: (a) providing a model animal, and completely anesthetizing the model animal; (b) the liver of the model animal is taken out, and the surgical resection proportion is determined; and (c) fixing the liver part needing to be cut by using a surgical suture line, and performing liver cutting. According to the method disclosed by the invention, the liver injury mouse model can be more efficiently constructed, and liver injury proportions required by different liver injury models can be met.

The invention relates to the field of medicine, and discloses a manufacturing method of a 3D printing liver cancer resection operation guide plate, which comprises the following steps: CT data acquisition: performing liver enhanced scanning to obtain multi-stage DICOM format data; a liver resection range is planned and a surgical section is determined by applying 3D visualization software on the basis of a portal vein 4-level branch drainage basin; 3-matic Medial and other engineering software are applied, and the liver surface and parenchyma inner operation guide plate is designed based on the operation section; a 3D printer is used for printing the digital operation guide plate into a physical model for operation positioning and navigation. Traditional liver cancer operation planning is established on the basis of a standard liver segmentation method and is lack of individuation. At present, the problems of complicated operation, low success rate, poor repeatability and the like exist when a liver pedicle blocking method and a dye injection method are mainly applied to surgical path navigation. The invention relates to a manufacturing method of a 3D printing liver cancer resection operation guide plate. Scientific planning and accurate navigation of an operation are realized through a 3D digital technology. Through the technical method, the radical treatment and safety of an operation are improved, and the liver cancer treatment effect is improved.

The present invention discloses the use of an acetyl-CoA (Ac‑CoA) promoter in the preparation of a drug for promoting liver regeneration. The present invention utilizes a mouse partial hepatectomy model and administers GS‑0976 before hepatectomy to increase Ac‑CoA in the liver. The results show that increased Ac‑CoA in the liver has the ability to improve liver function after liver injury and promote hepatocyte proliferation. The mechanism involves Ac‑CoA promoting MSL1 phase separation, increased STAT3 and H4K16 acetylation, which manifests as significantly upregulated cell cycle-related genes and increased hepatocyte proliferation. The experimental results show that increasing liver Ac‑CoA levels has the effect of promoting liver regeneration, providing a new solution for the recovery and treatment of hepatectomy and its complications.

This invention discloses the application of β-hydroxybutyric acid (BHB) in the preparation of products that promote hepatocyte proliferation and liver regeneration. This invention discovers that β-hydroxybutyric acid can promote liver regeneration and recovery by promoting the proliferation of hepatocytes in the residual liver after partial hepatectomy. Therefore, β-hydroxybutyric acid can be used to prepare products that promote liver regeneration. This invention not only discloses the application of β-hydroxybutyric acid in promoting liver regeneration, providing a drug source for the development of products that promote liver regeneration, but also provides a theoretical basis for subsequent clinical intervention strategies to promote liver regeneration. This helps to improve liver regeneration capacity and avoid poor prognosis and liver failure caused by insufficient liver regeneration capacity after partial hepatectomy or living donor liver transplantation.

The invention relates to the field of biological medicine, and discloses application of a reagent for promoting expression of an LECT2 gene in preparation of a medicine for promoting liver regeneration, application of the reagent for promoting expression of the LECT2 gene in preparation of the medicine for promoting liver regeneration and the medicine for promoting liver regeneration with overexpressed LECT2 as a main active component. According to the present invention, with the application of the virus vector, the liver regeneration after the liver resection can be promoted, the AAV9-Lect2 or the control (AAV9-Ctrl) is injected into the C57BL / 6J mouse body through the overexpression of the virus vector, the molding succeeds after 4 weeks, the 2 / 3 resection operation of the liver is performed on the two groups of mice, and the sample is collected after 48 h; the result shows that in the mouse treated by AAV9-Lect2, the expression of LECT2 in the liver is obviously increased. Compared with a control group, mice subjected to AAV9-Lect2 treatment show more proliferative hepatocytes, the immunohistochemical staining results of Ki67 and PCNA are more remarkable, and LECT2 has potential application value in drugs for promoting liver regeneration and treatment.

The invention belongs to the field of medicines, and discloses application of macastine B in preparation of anti-inflammatory, repair-promoting and relapse and metastasis-resisting medicines after liver cancer operation. The invention discloses an application of macastine B in preparation of a medicine for recovering a liver cancer patient after partial liver resection. The macaxantin B can promote liver function recovery, reduce the level of inflammatory factors of liver tissues and serum species, and reduce the tumor recurrence rate and the tumor visceral metastasis rate after tumor excision after an orthotopic liver cancer surgical operation, and compared with simultaneous administration of a liver protection drug and an anti-tumor drug, the macaxantin B has the advantages that the liver metabolism burden is reduced, and the curative effect is improved. And a novel drug treatment choice is provided for disease management of a liver cancer patient in a perioperative period. The invention discloses a medicine for promoting postoperative recovery of an orthotopic liver cancer surgical operation. The medicine comprises an effective therapeutic dose of macastine B and pharmaceutically acceptable auxiliary materials.

This invention relates to the field of liver cancer biomarker technology. The invention provides a cfDNA gene mutation scoring system to guide liver cancer treatment selection, along with specific biomarkers used: the TP53 gene, AXIN1 gene, VCAN gene, and FBN3 gene. The biomarkers of this invention can classify early-stage liver cancer patients into low-micrometastasis risk subgroups and high-micrometastasis risk subgroups. By performing high-depth capture sequencing on peripheral blood cfDNA isolated preoperatively and detecting mutations in the four genes TP53, AXIN1, VCAN, and FBN3, early-stage liver cancer patients are differentiated into different risk subgroups. Different surgical margins are then selected for different subgroups during liver resection surgery. By using the biomarkers of this invention to classify the risk level of early-stage liver cancer, the selection of surgical margins can be further guided, improving the accuracy of surgical treatment selection for this type of liver cancer and achieving better survival prognosis.

The application relates to a dynamic three-dimensional reconstruction method and system for liver resection, which comprises the following steps: obtaining initial mesh data based on preoperative CT images; obtaining two-dimensional projection images of a surgical area by using intraoperative CT to obtain target mesh data; constructing surface models by using the target mesh data and the initial mesh data respectively and performing rigid registration, and demarcating a model surface part with a larger deformation region as a to-be-reconstructed space; performing non-rigid deformation on the initial mesh region in the to-be-reconstructed space to reconstruct a high-resolution surface model of the to-be-reconstructed space; and replacing the corresponding part of the preoperative full-liver tissue accurate three-dimensional surface model with the generated high-resolution surface model of the to-be-reconstructed space. Compared with the prior art, the application solves the problems of high time complexity, high computing power requirement and incapability of dynamic monitoring of a local region in the prior art, realizes rapid reconstruction of a liver tissue surface of a surgical area in operation, and achieves the purpose of dynamic monitoring and auxiliary accurate resection in operation.

The application discloses a device and method for blocking liver blood flow during liver resection surgery, comprising a fixed frame group, a buckle assembly and a water injection bag; the fixed frame group is composed of a No. 1 frame, a No. 2 frame, a connecting sheet, a hinge nail, a No. 1 connecting block and a No. 2 connecting block; the patient's hepatoduodenal ligament is wrapped by the fixed frame group, and then water is injected into the water injection bag by using a water injection pipe, so that the blood flow of the patient's hepatoduodenal ligament can achieve a satisfactory blocking effect, and the liver portal blood flow blocking during liver resection becomes easier to operate and control, thereby greatly reducing the intraoperative bleeding amount; in addition, when the device is used for liver blood flow blocking, the force on the tissue is uniform, the damage to important structures in the hepatoduodenal ligament during blocking is reduced, and the occurrence of postoperative complications is reduced, thereby being beneficial to the recovery of the patient, and therefore, the device has the advantages of simple use, good effect, small tissue damage and the like, and is worthy of promotion and use in medical institutions.

The invention discloses an injectable decellularized matrix-liver organ three-dimensional compound as well as a preparation method and application thereof. The three-dimensional compound comprises decellularized matrix fibers and liver organs which form a pasty compound, the length of the decellularized matrix fiber is 0.2-2mm, and the decellularized matrix fiber is obtained by selecting mammalian dermis, performing epidermis removal and degreasing, performing soaking treatment with alkali and a nonionic surfactant in sequence, then performing decellularization, and performing freeze-drying and ball milling. The liver organ is obtained by placing bile in matrigel for culture, amplification and induction. According to the invention, a Mini-liver complex with injectability, self-adhesion, biological activity and metabolic function is formed, unified integration of a material scaffold, signal delivery and cell function is realized, and an innovative solution with remarkable clinical potential is provided for local repair after hepatic resection and hepatic failure.

The invention discloses a biomarker for hepatic ischemia reperfusion injury based on proteomics, the biomarker is NGP (Neutrophil Granule Protein), and the biomarker can be used for early diagnosis and prevention, prognosis monitoring and judgment and the like of complications after hepatic resection.

The invention provides a laparoscopic liver resection operation registration method and system based on an artificial intelligence algorithm, and belongs to the technical field of image processing. The method comprises the following steps: performing normalization processing on a preprocessed laparoscopic surgery image to obtain a normalized laparoscopic surgery image; performing contour extraction on the normalized laparoscopic surgery image by adopting an artificial intelligence algorithm to obtain an upper edge and a lower edge of the liver of the laparoscopic surgery image; constructing a preoperative 3D liver model, and marking the upper edge and the lower edge of the liver in the constructed preoperative 3D liver model; and performing registration calculation on the upper edge and the lower edge of the liver in the laparoscopic surgery image and the upper edge and the lower edge of the liver marked in the constructed preoperative 3D liver model to obtain a registration result. Compared with the prior art, the method effectively solves the problem that the accuracy of registration of the laparoscopic liver resection operation is not high.

This invention discloses an injury-related endogenous polypeptide and its applications. The invention employs a "single-model initial screening – multi-model cross-validation" strategy, using an acute lung injury (ALI) model as the screening set and partial hepatectomy (PHx) and cerebral ischemia-reperfusion injury (tMCAO) models as the validation set. Combined with liquid chromatography-tandem mass spectrometry (LC-MS / MS) technology, a group of serum endogenous polypeptides was screened. These polypeptides are novel epitope fragments generated by specific enzymatic digestion of precursor proteins such as fibrinogen α-chain and hemoglobin α / β subunits in the tissue injury microenvironment. Their expression levels are extremely low in healthy serum but exhibit explosive upregulation in injured states. Experiments have confirmed that this group of polypeptides shows significant responses in acute lung injury, liver injury, and cerebral ischemia-reperfusion injury models, and can serve as broad-spectrum biomarkers for multi-tissue injury, providing a novel detection target for the early diagnosis of multi-tissue injury in acute and critical clinical settings.

The application provides application of quinoline-4-carboxylic acid in preparation of anti-aging products and products for protecting liver and promoting liver regeneration, and belongs to the technical field of medicines.The application finds that quinoline-4-carboxylic acid can be used as a novel additive for in-vitro expansion culture of mesenchymal stem cells, breaks the bottleneck of easy aging of mesenchymal stem cells in in-vitro culture, and optimizes the clinical development and application of the mesenchymal stem cells; quinoline-4-carboxylic acid can relieve aging-related phenotypes of fruit flies and mice, enhance the movement ability of fruit flies and the muscle strength of mice, prolong the life span of fruit flies and mice, and is expected to become an effective component of anti-aging therapeutic drugs; quinoline-4-carboxylic acid can improve the survival rate of mice after liver resection, promote liver regeneration after liver resection injury, and is expected to become an effective component of drugs for promoting the prognosis of patients after liver resection, promoting liver regeneration, relieving or treating liver injury and the like.

The invention belongs to the field of biological medicine, and particularly relates to application of CD177 positive neutrophil in liver regeneration. A series of experiments reveal that neutrophil is an immune cell necessary for liver regeneration after a liver resection operation, especially after a two-step liver resection operation (ALPPS) combining liver separation and portal vein ligation, and after the neutrophil is depleted by an antibody, liver cell proliferation and liver volume increase are remarkably inhibited. The invention further finds that the CD177 positive neutrophil is a specific functional subgroup which plays a key role in the CD177 positive neutrophil. Liver regeneration can be obviously inhibited by clearing the CD177 positive neutrophil in the mouse body, and inhibited liver regeneration can be recovered by in-vivo feedback of the CD177 positive neutrophil. The invention discloses an unknown effect of the CD177 positive neutrophil in promotion of ALPPS induced liver regeneration previously. The research lays a foundation for a strategy taking the neutrophil as a target spot, and a regenerative liver microenvironment is expected to be established and is used for preventing and treating hepatic failure.

The invention discloses an application of quercetin and silibinin in preparation of a medicine for promoting liver regeneration. Mouse partial liver resection model experiments prove that quercetin and quercetin and silybin combined medication can remarkably improve the liver weight ratio, liver cell proliferation is further promoted by activating a prostaglandin D2 receptor 1, especially liver regeneration after partial liver resection is promoted, and the effects of repairing liver injury and promoting liver proliferation are achieved.

The application discloses application of PLIN5 as a target point in development, screening or preparation of a drug for promoting liver regeneration, and the development or screening comprises the following steps: S1, contacting a candidate compound with a cell expressing PLIN5 or a system containing PLIN5 protein; S2, detecting the influence of the candidate compound on the expression level or biological activity of PLIN5; S3, selecting the candidate compound capable of up-regulating the expression level of PLIN5 or enhancing the activity thereof. The application firstly finds that PLIN5 is a key positive regulation target point of liver regeneration, fills the research blank of PLIN5 in the field of liver regeneration regulation in the prior art, and provides a new theoretical basis for the molecular mechanism research of liver regeneration. The up-regulator based on PLIN5 has a clear promoting effect on liver regeneration, can be used for improving the liver function recovery after liver injury, and provides a new drug research and development direction for prevention of postoperative complications of liver resection, treatment of liver fibrosis, alcoholic liver and other diseases.

The present invention relates to a method for constructing a prediction model for vascular exposure during liver resection based on anatomy, including constructing the geometric structure of the liver and blood vessels based on CT and MRI data, and introducing biomechanical property modeling; combining the principles of biomechanics, the model simulates the stress and strain behavior of blood vessels under different physiological conditions and their response when surgical instruments apply pressure through finite element analysis (FEA); providing a static anatomical structure, and the prediction model provides basic data on dynamic factors of vascular elasticity and toughness; introducing a hierarchical branch complexity model, classifying the vascular branch network according to the number of branches, angles, and diameter change characteristics, and analyzing the difficulty of vascular exposure at different levels; establishing vascular exposure scenarios under different intraoperative operation paths through surgical dynamic simulation based on a physics engine; including predicting deformation or micro-displacement caused when the instrument contacts the tissue around the blood vessel during surgery.

The invention discloses a multifunctional dissector for laparoscopic liver resection, and relates to the technical field of medical instruments. The multifunctional dissector for laparoscopic liver resection comprises an instrument rod, a suction system assembly and a scraping and suction cooperation assembly, the suction system assembly is arranged at the front end of the instrument rod, the scraping and suction cooperation assembly is arranged at the rear end of the instrument rod, the rear end of the instrument rod is connected with a grab handle body, the grab handle body is provided with a flushing flow adjusting knob, and a tool bit body is provided with an oblique incision, a universal ball joint and an adjustable flushing opening. According to the multifunctional dissector for laparoscopic liver resection, scraping and suction linkage, precise flushing and efficient suction are achieved, a small amount of errhysis can be removed within five seconds, clear view is guaranteed, one-hand operation is convenient and fast, surgical risks and maintenance cost are reduced, and the multifunctional dissector is suitable for conventional laparoscopic liver resection surgery.

The invention provides application of phosphatidylcholine (PC) 16: 0 / 20: 4 in preparation of a medicine for promoting liver regeneration, and the phosphatidylcholine (PC) 16: 0 / 20: 4 is used for promoting liver regeneration and repair in vivo or in vitro. The PC16: 0 / 20: 4 has better effects of repairing liver injury and promoting liver proliferation, can effectively promote liver regeneration and repair, provides a new choice for treating complications such as acute liver injury, liver failure and the like after partial liver resection, and has important scientific research and clinical application values.

The PHLF risk prediction model based on a machine learning algorithm and a construction method thereof belong to the field of medical data processing, and include the following steps: original clinical data collection, data preprocessing, core risk factor screening, data set division, model verification and optimization, and model explanation optimization.The construction of the PHLF risk prediction model relies on the full-dimension preoperative clinical data of hepatocellular carcinoma patients who have undergone liver resection collected from a hospital routine information system, and can be completed in combination with a high-performance computing platform without relying on complex instruments and equipment.Compared with traditional evaluation methods, the present application breaks through the limitations of human experience, realizes the intelligentization and precision of PHLF risk prediction through massive data training and verification, and exhibits significant scientificity and advancement in the field of perioperative management of liver cancer.The wide application of the present application in the clinic can quickly quantify the postoperative PHLF risk and assist clinicians in making accurate decisions.

The embodiment of the invention provides a real-time liver volume evaluation method based on liver surface reconstruction in digital twin surgery, and relates to the field of medicine and artificial intelligence. The method comprises the following steps: acquiring a first three-dimensional model of the liver, wherein the first three-dimensional model is generated based on image data which is acquired before an operation and is related to the liver; the method comprises the following steps: acquiring image data of the liver in the liver resection; extracting feature information related to the liver based on the image data, and performing feature matching based on the extracted feature information; based on a feature matching result, reconstructing a second three-dimensional model of the liver; performing point cloud registration on the first three-dimensional model and the second three-dimensional model; and performing liver volume evaluation based on a point cloud registration result. According to the method, the liver model can be reconstructed in real time in the operation, and the accuracy of liver volume evaluation is improved.

The application provides a liver tumor resection effect prediction tool based on an adversarial generative network, comprising a trained deep learning model, wherein the deep learning model comprises a first model and a second model; the first model is used to output postoperative enhanced MRI data according to preoperative enhanced MRI data and a liver resection range; and the second model is used to output a recurrence rate evaluation result by taking preoperative serum tumor marker data and the postoperative enhanced MRI data output by the first model as input. The application can give a relatively accurate postoperative prediction result based on existing data (preoperative liver enhanced MRI data, preoperative serum tumor marker data) and a surgical plan (liver resection range) before operation, and can also provide visualized prediction of images, which is of great significance for the prognosis of treatment and the determination of the liver resection range before operation.

The application relates to the field of biological medicine, in particular to application of sodium tiglate in preparation of products for promoting liver regeneration and reducing blood ammonia; it is found and disclosed for the first time in the application that sodium tiglate can be applied to preparation of liver regeneration or liver function recovery products, liver cell proliferation capacity of residual liver after partial hepatectomy can be improved by using sodium tiglate, blood ammonia level after liver surgery is controlled, nitrogen metabolism disorder is improved by promoting conversion of blood ammonia into urea, and liver cell regeneration capacity is improved; the application of sodium tiglate provides a new treatment strategy with clear action mechanism and wide development prospect for treatment of insufficient liver regeneration after partial hepatectomy and hyperammonemia.